Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Declines By 92.1%

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 19,000 shares, a decrease of 92.1% from the December 15th total of 241,700 shares. Based on an average trading volume of 325,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.3% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. StockNews.com began coverage on shares of Aptevo Therapeutics in a report on Monday, December 9th. They set a “sell” rating for the company. Roth Mkm cut their target price on shares of Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Stock Down 3.3 %

Shares of NASDAQ:APVO traded down $0.16 during trading on Monday, reaching $4.63. The company’s stock had a trading volume of 43,086 shares, compared to its average volume of 79,684. The firm’s 50 day simple moving average is $169.54 and its two-hundred day simple moving average is $334.86. Aptevo Therapeutics has a 12 month low of $3.65 and a 12 month high of $399.60.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.